Brean Murray Assumes Coverage on Immunomedics (IMMU) with a Buy; Significantly Undervalued
IMMU Hot Sheet
Rating Summary:5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Brean Murray assumes coverage on Immunomedics (Nasdaq: IMMU) with a Buy rating and target price of $8
Brean analyst says, "We strongly believe the company is significantly undervalued given its broad pipeline with 5 product candidates in multiple clinical programs, significant near-term news flow, strong technologies and a healthy cash position. We expect the progress of internal and partnered programs, and potential additional partnerships to drive shareholder value."
To see more analyst ratings on IMMU Click Here.
Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, autoimmune, and other serious diseases.
Brean analyst says, "We strongly believe the company is significantly undervalued given its broad pipeline with 5 product candidates in multiple clinical programs, significant near-term news flow, strong technologies and a healthy cash position. We expect the progress of internal and partnered programs, and potential additional partnerships to drive shareholder value."
To see more analyst ratings on IMMU Click Here.
Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, autoimmune, and other serious diseases.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- DA Davidson Starts Belden, Inc. (BDC) at Neutral; Attractive Long-Term, Pressure From Europe Short-Term
- Credit Suisse Starts Carrizo Oil & Gas (CRZO) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
